China
Africa
Explore chapters and articles related to this topic
Benign Neoplasms
Published in Ayşe Serap Karadağ, Lawrence Charles Parish, Jordan V. Wang, Roxburgh's Common Skin Diseases, 2022
Abdullah Demirbaş, Ömer Faruk Elmas, Necmettin Akdeniz
Clinical presentation: Infantile hemangioma is the most common tumor of infancy, with a rate of 2–10% in newborns. This tumor, which is more common in girls, typically occurs within the first weeks of life. It located in the skin and soft tissues as a solitary lesion on the head or neck (Figure 19.16). It can also occur on the trunk, arms, legs, and visceral organs.
Liver resection
Published in Mark Davenport, James D. Geiger, Nigel J. Hall, Steven S. Rothenberg, Operative Pediatric Surgery, 2020
Rebecka L. Meyers, Zachary Kastenberg, Max Langham
Diffuse infantile hemangioma may occasionally be quite large and, when symptomatic, contemporary treatment includes propranolol and treatment of congestive heart failure caused by intratumoral arteriorvenous shunting; surgery and/or embolization is rarely necessary. Other benign tumors include mesenchymal hamartoma, biliary cystadenoma, hepatic adenoma, focal nodular hyperplasia (FNH), macroregenerative nodules, dysplastic nodules, and pseudoinflammatory myofibroblastic tumors.
How extensive study should be included in initial assessment for congenital vascular malformations
Published in Byung-Boong Lee, Peter Gloviczki, Francine Blei, Jovan N. Markovic, Vascular Malformations, 2019
But a thorough history taking and detailed physical examination should provide most of the critical information necessary to reach the suspicion for CVMs. Further confirmation of a clinical impression of CVMs can be achieved with basic laboratory tests. Such evaluation should start with a differential diagnosis to first rule out a similar vascular condition known as (infantile) hemangioma, especially when encountered during the neonatal period. Infantile hemangioma can be mostly diagnosed based on careful history alone through proper confirmation on its new appearance after the birth as a newly developed vascular tumor and if not, with further findings of its unique clinical progress with rapid growth. But occasionally, Duplex ultrasonography might be added to make its final confirmation.1–4
Letter to editor regarding “Clinical practice guidelines on management of infantile hemangioma: a systematic quality appraisal using the AGREE II instrument”
Published in Pediatric Hematology and Oncology, 2023
Ilona J. Frieden, Anthony J. Mancini, Francine Blei, David H Darrow, Daniel P. Krowchuk
We read with interest the article by De Ravin et al “Clinical practice guidelines on management of infantile hemangioma: a systematic quality appraisal using the AGREE II instrument” and would like to comment on their findings. We would like to point out a major omission in their study.1 In 2019, the American Academy of Pediatrics (AAP) published Clinical Practice Guidelines (CPG) for management of infantile hemangiomas based on a rigorous evidence-based approach.2 These guidelines were developed via rigorous review and updating of a prior comparative effectiveness study performed on behalf of the Agency for Healthcare Research and Quality (AHRQ) of potential benefits and harms of diagnostic modalities and pharmacologic and surgical treatments.3 The original AHRQ report was augmented and updated via a thorough literature search (methods outlined in the statement) and review, for the period July 2015 to January 2017, to develop the CPG.
Clinical practice guidelines on management of infantile hemangioma: a systematic quality appraisal using the AGREE II instrument
Published in Pediatric Hematology and Oncology, 2022
Emma De Ravin, Louis-Xavier Barrette, Joseph Lu, Katherine Xu, Neeraj Suresh, Dominic Romeo, Alvaro Moreira, Karthik Rajasekaran
A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria.13 JL performed a systematic search of the MEDLINE (via PubMed), EMBASE, and SCOPUS databases using the search terms [(“infantile hemangioma” OR “vascular malformation” OR “venous malformation” OR “venous anomalies” OR “arterio-venous malformation”) AND (“guideline” OR “consensus” OR “recommendation” OR “management” OR “clinical practice guideline”)] in the title, abstract, author, or keywords. Inclusion criteria for our search included national and international guidelines published between time of database inception and August 8, 2021. All consensus or guideline statements concerning infantile hemangioma management that were available in English were included in this review. Guidelines that exclusively discussed hepatic hemangioma or IH in the setting of PHACE (Posterior fossa–brain malformations; Hemangiomas; Arterial, Cardiac, and Eye abnormalities) syndrome were excluded. Systematic reviews, primary studies, retrospective reviews, and textbook chapters were also excluded. Discussion between three authors (EDR, JL, KR) was used to resolve any conflicts or differences in guideline inclusion/exclusion.
Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma
Published in Journal of Dermatological Treatment, 2020
Hanan H. Sabry, Neveen E. Sorour, Essam M. Akl
Infantile hemangioma (IH) is the commonest infantile vascular tumor (1). Although IH has a self-limiting course, several complications may occur such as ulceration, vision affection, secondary infection, feeding and airway obstructions and even death (2). The treatment indications of IH depends of risk of functional impairment, bleeding risk and disfigurement potentiality (3). The precise pathogenetic inducer responsible for IH development is still an enigma; however, several theories have been suggested such as tissue hypoxia, embolization of placental endothelial cells and imbalance between angiogenic and vasculogenic activity (4). The over-expression of vascular endothelial growth factor (VEGF) in early proliferative phase of IH followed by decreased expression in involuting phase may indicate its role in IH pathogenesis (5).